Semagacestat (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Semagacestat" in English language version.

refsWebsite

Global rank English rank

5,225^th place

4,062^nd place

2^nd place

4^th place

11^th place

8^th place

low place

low place

clinicaltrials.gov

Clinical trial number NCT00594568 for "Effect of LY450139 on the Long Term Progression of Alzheimer's Disease" at ClinicalTrials.gov
Clinical trial number NCT00762411 for "Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo (IDENTITY-2)" at ClinicalTrials.gov
Clinical trial number NCT00762411 for "A Study in Semagacestat for Alzheimer's Patients (Identity XT)" at ClinicalTrials.gov

Yi P, Hadden C, Kulanthaivel P, Calvert N, Annes W, Brown T, et al. (April 2010). "Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans". Drug Metabolism and Disposition. 38 (4): 554–65. doi:10.1124/dmd.109.030841. PMID 20075192. S2CID 19707025.
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. (July 2008). "Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial". Lancet. 372 (9634): 216–23. doi:10.1016/S0140-6736(08)61075-2. PMID 18640458. S2CID 18340153.

Yi P, Hadden C, Kulanthaivel P, Calvert N, Annes W, Brown T, et al. (April 2010). "Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans". Drug Metabolism and Disposition. 38 (4): 554–65. doi:10.1124/dmd.109.030841. PMID 20075192. S2CID 19707025.
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. (July 2008). "Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial". Lancet. 372 (9634): 216–23. doi:10.1016/S0140-6736(08)61075-2. PMID 18640458. S2CID 18340153.

Yi P, Hadden C, Kulanthaivel P, Calvert N, Annes W, Brown T, et al. (April 2010). "Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans". Drug Metabolism and Disposition. 38 (4): 554–65. doi:10.1124/dmd.109.030841. PMID 20075192. S2CID 19707025.
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. (July 2008). "Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial". Lancet. 372 (9634): 216–23. doi:10.1016/S0140-6736(08)61075-2. PMID 18640458. S2CID 18340153.